These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

104 related items for PubMed ID: 2924878

  • 21. Randomized, controlled, double-blind trial of topical treatment of cutaneous leishmaniasis with paromomycin plus methylbenzethonium chloride ointment in Guatemala.
    Arana BA, Mendoza CE, Rizzo NR, Kroeger A.
    Am J Trop Med Hyg; 2001 Nov; 65(5):466-70. PubMed ID: 11716099
    [Abstract] [Full Text] [Related]

  • 22. Comparison of the effectiveness of two topical paromomycin treatments versus meglumine antimoniate for New World cutaneous leishmaniasis.
    Armijos RX, Weigel MM, Calvopiña M, Mancheno M, Rodriguez R.
    Acta Trop; 2004 Jul; 91(2):153-60. PubMed ID: 15234664
    [Abstract] [Full Text] [Related]

  • 23. Topical treatment of cutaneous leishmaniasis in Belize: in vitro and in vivo studies with Leishmania mexicana.
    el-On J, Cawich F, Evans DA, Weinrauch L.
    Int J Parasitol; 1993 Feb; 23(1):121-7. PubMed ID: 8468127
    [Abstract] [Full Text] [Related]

  • 24. A double-blind clinical trial of the treatment of cutaneous leishmaniasis with paromomycin ointment.
    el-Safi SH, Murphy AG, Bryceson AD, Neal RA.
    Trans R Soc Trop Med Hyg; 1990 Feb; 84(5):690-1. PubMed ID: 2278070
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Topical paromomycin/methylbenzethonium chloride plus parenteral meglumine antimonate as treatment for American cutaneous leishmaniasis: controlled study.
    Soto J, Fuya P, Herrera R, Berman J.
    Clin Infect Dis; 1998 Jan; 26(1):56-8. PubMed ID: 9455509
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Successful treatment of New World cutaneous leishmaniasis with a combination of topical paromomycin/methylbenzethonium chloride and injectable meglumine antimonate.
    Soto J, Hernandez N, Mejia H, Grogl M, Berman J.
    Clin Infect Dis; 1995 Jan; 20(1):47-51. PubMed ID: 7727669
    [Abstract] [Full Text] [Related]

  • 30. Is paromomycin an effective and safe treatment against cutaneous leishmaniasis? A meta-analysis of 14 randomized controlled trials.
    Kim DH, Chung HJ, Bleys J, Ghohestani RF.
    PLoS Negl Trop Dis; 2009 Jan; 3(2):e381. PubMed ID: 19221595
    [Abstract] [Full Text] [Related]

  • 31. Treatment of cutaneous leishmaniasis with 20% paromomycin ointment.
    Stanimirović A, Stipić T, Skerlev M, Basta-Juzbasić A.
    J Eur Acad Dermatol Venereol; 1999 Nov; 13(3):214-7. PubMed ID: 10642059
    [Abstract] [Full Text] [Related]

  • 32. Solid lipid nanoparticle loaded with paromomycin: in vivo efficacy against Leishmania tropica infection in BALB/c mice model.
    Heidari-Kharaji M, Taheri T, Doroud D, Habibzadeh S, Rafati S.
    Appl Microbiol Biotechnol; 2016 Aug; 100(16):7051-60. PubMed ID: 26960322
    [Abstract] [Full Text] [Related]

  • 33. Comparative study of the efficacy of formulations containing fluconazole or paromomycin for topical treatment of infections by Leishmania (Leishmania) major and Leishmania (Leishmania) amazonensis.
    Mussi SV, Fernandes AP, Ferreira LA.
    Parasitol Res; 2007 May; 100(6):1221-6. PubMed ID: 17206508
    [Abstract] [Full Text] [Related]

  • 34. Cutaneous leishmaniasis. The defect in T cell influx in BALB/c mice.
    McElrath MJ, Kaplan G, Nusrat A, Cohn ZA.
    J Exp Med; 1987 Feb 01; 165(2):546-59. PubMed ID: 3546576
    [Abstract] [Full Text] [Related]

  • 35. The lack of effectiveness of hyperbaric oxygenation as a treatment for Leishmania major in a mouse model.
    Livneh A, Youngster I, El-On Y, Berkovitch M, Abu-Kishk I.
    Acta Parasitol; 2015 Jun 01; 60(2):345-9. PubMed ID: 26204005
    [Abstract] [Full Text] [Related]

  • 36. Topical treatment of New World cutaneous leishmaniasis in Belize: a clinical study.
    Weinrauch L, Cawich F, Craig P, Sosa JX, el-On J.
    J Am Acad Dermatol; 1993 Sep 01; 29(3):443-6. PubMed ID: 8349861
    [Abstract] [Full Text] [Related]

  • 37. S-nitrosoglutathione (GSNO) is cytotoxic to intracellular amastigotes and promotes healing of topically treated Leishmania major or Leishmania braziliensis skin lesions.
    Costa IS, de Souza GF, de Oliveira MG, Abrahamsohn Ide A.
    J Antimicrob Chemother; 2013 Nov 01; 68(11):2561-8. PubMed ID: 23788476
    [Abstract] [Full Text] [Related]

  • 38. Combined interleukin-12 and topical chemotherapy for established Leishmaniasis drastically reduces tissue parasitism and relapses in susceptible mice.
    Fernandes AP, Carvalho FA, Tavares CA, Santiago HC, Castro GA, Tafuri WL, Ferreira LA, Gazzinelli RT.
    J Infect Dis; 2001 Jun 01; 183(11):1646-52. PubMed ID: 11343214
    [Abstract] [Full Text] [Related]

  • 39. Combined suboptimal schedules of topical paromomycin, meglumine antimoniate and miltefosine to treat experimental infection caused by Leishmania (Viannia) braziliensis.
    de Morais-Teixeira E, Aguiar MG, Soares de Souza Lima B, Ferreira LA, Rabello A.
    J Antimicrob Chemother; 2015 Dec 01; 70(12):3283-90. PubMed ID: 26346991
    [Abstract] [Full Text] [Related]

  • 40. Colloidal, in vitro and in vivo anti-leishmanial properties of transfersomes containing paromomycin sulfate in susceptible BALB/c mice.
    Bavarsad N, Fazly Bazzaz BS, Khamesipour A, Jaafari MR.
    Acta Trop; 2012 Oct 01; 124(1):33-41. PubMed ID: 22750480
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.